Effect of vitamin E and human placenta cysteine peptidase inhibitor on expression of cathepsins B and L in implanted hepatoma Morris 5123 tumor model in Wistar rats

Table 1 Cathepsins B, L and their inhibitor activities, survival time and the total cure responses of hepatoma morris-5123 in Wistar rats before and after treatment in comparison with negative control (median, mean±SD, range).

	Cathepsins B, L(mEU/mg)	Inhibitor (CPI80)(mEU/mg)	Inhibitor (CPI37)(mEU/mg)	Complex form (△CPI) (mEU/mg)	Survival time (d)	Cure(yes/No)	Value(P)
Control negative	5.8	24.7	10.5	14.2
(healthy)	6.5±1.7	25.4±8.9	11.2±2.8	14.2±6.1	60	10/10	0.0005
	(2.4-8.2)	(12.6-40.7)	(2.4-14.5)	(10.2-26.2)
Control positive	88.5	17.5	8.5	9	09–12
(Tumor)	85.4±12.6	18.8±8.6	9.3±1.2	9.5±7.4	-10.5	2/10	0.0001
	(10.5-123.9)	(4.6-23.8)	(1.4-12.5)	(3.2-11.3)
Tumor+ 10 mg Vit E	80.5	28.7	16.4	12.3	12-26
	81.8±20.6	29.5±12.0	17.0±5.5	12.5±6.5	-19	2/10	0.0005
	(11.0-99.8)	(6.7-35.7)	(3.9-20.3)	(2.8-15.4)
Tumor+20 mg Vit E	78.7	35.6	20.3	15.3	15-30
	79.4±20.4	36.6±15.0	21.5±4.6	15.1± 10.4	-22.5	3/10	0.0005
	(10.7-97.4)	(7.3-40.1)	(4.2-22.0)	(3.1-18.1)
Tumor+ 200 μg CPI	56.5	46.3	35.8	10.5	16-30
	57.4±15.1	47.7±20.0	37.0±17.6	10.7±2.4	-23	3/10	0.0001
	(22.1-80.6)	(12.3-52.9)	(9.0-40.0)	(3.3-12.9)
Tumor+ 400 μg CPI	47.9	67.8	46.8	21	18-35
	48.7±18.6	69.0±25.2	47.3±16.0	21.7±9.2	-21.5	4/10	0.0001
	(23.2-68.9)	(20.6-88.5)	(14.4-60.1)	(6.2-28.4)
Tumor+ 10 mg Vit E +Tumor+ 200 µg CPI	41.8	71.8	52.3	18.5	27-38
	43.0±10.6	73.0±25.4	53.6±22.1	19.4±3.3	-32.5	4/10	0.0001
	(12.0-46.7)	22.7-82.8	(20.4-63.3)	(2.3-11.5)
Tumor+ 10 mg Vit E +Tumor+ 400 µg CPI	30.2	82.2	61	21.2	30-40
	31.6±12.0	83.5±29.8	62.4±25.5	21.1±4.3	-35	5/10	0.0001
	(9.8-38.7)	(26.9-93.7)	(24.6-70.2)	(2.3-23.5)
Tumor+ 20 mg Vit E +Tumor+ 200 µg CPI	15.4	94.4	74.2	10.2	38-60
	16.5±2.8	95.8±35.4	75.6±33.1	10.2±2.3	-49	6/10	0.0001
	(6.4-20.8)	(37.8-112.7)	(32.3-94.5)	(5.5-18.2)
Tumor+ 20 mg Vit E+Tumor+ 400 µg CPI	7.5	120.8	105.5	15.3	45-60
	8.4±1.8	122.0±43.6	107.0±39.2	15.0±4.4	-52.5	7/10	0.0001
	(2.6-10.2)	(45.8-135.5)	(35.6-118.2)	(10.2-17.3)

The significance of the differences in Medan values of tumor and control tissues was calculated by Wilcoxon matched pair’s signed-rank test.

Table 2 Activity values of cathepsins B and L and their inhibitors in hepatoma Morris 5123 (median, mean±SD, range).

	Before treatment			After treatment
	Cathepsin B	Cathepsin L	Endogenous (CPI)	Cathepsin B	Cathepsin L	Endogenous (CPI)
	8.2	3.2	12.2
Control negative(Healthy)	9.4±1.5	3.6±1.3	12.8±2.6		No changes
	(1.5-12.7)	(1.3-7.4)	(3.4-15.7)
	67.6	28.4	8.5	7.6	3.4	78.5
Control positive (Tumor)	68.9±23.6	28.8±10.4	9.0±2.3	8.4±2.5	3.8±1.6	79.4±22.5
	(19.4-89.2)	(6.4-35.2)	(3.2-12.5)	(3.4-10.2)	(2.2-5.7)	(23.9-96.5)
	46.6	17.2	4.3	6.3	2.2	63.2
Liver	47.9±20.5	18.8±8.6	5.6±1.1	7.8±2.9	2.7±1.0	64.8±25.7
	(21.3-68.2)	(6.4-25.8)	(1.8-7.7)	(2.9-8.6)	(1.2-5.4)	(27.9-74.3)
	26.7	10.8	3.6	2.6	1.5	45.8
Lung	27.9±18.3	12.0±4.2	4.6±0.9	2.9±0.5	2.0±0.4	47.1±21.5
	(15.8-38.9)	(6.4-19.4)	(1.0-6.8)	(0.8-3.7)	(0.4-3.1)	(23.7-56.0)
	12.6	8	1.2	1.5	1.6	114.8
Sera	13.9±4.2	9.3±2.8	1.6±0.1	3.7±0.9	1.7±0.6	115.3±45.4
	(5.6-18.5)	(2.9-11.3)	(0.2-2.3)	(0.04-3.2)	(0.07-3.8)	(44.7-123.9)
P		≤0.0001		NS	NS	≤0.0001

The significance of differences in median values of tumor and control were calculated after and before treatment by Wilcoxon rank test. NS, Not significant.